Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glottis | 3 | 2023 | 20 | 1.000 |
Why?
|
| Brain Stem | 1 | 2024 | 96 | 0.820 |
Why?
|
| Precision Medicine | 2 | 2024 | 434 | 0.800 |
Why?
|
| Brain Mapping | 1 | 2024 | 532 | 0.690 |
Why?
|
| Vocal Cords | 5 | 2023 | 32 | 0.680 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2023 | 567 | 0.610 |
Why?
|
| Atherosclerosis | 1 | 2021 | 404 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 882 | 0.500 |
Why?
|
| Vibration | 4 | 2023 | 75 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3709 | 0.360 |
Why?
|
| Dogs | 5 | 2023 | 427 | 0.350 |
Why?
|
| Phonation | 4 | 2023 | 13 | 0.340 |
Why?
|
| Metformin | 2 | 2024 | 333 | 0.310 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2087 | 0.310 |
Why?
|
| Ivermectin | 2 | 2024 | 14 | 0.250 |
Why?
|
| Fluvoxamine | 2 | 2024 | 17 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 420 | 0.220 |
Why?
|
| Touch Perception | 1 | 2024 | 19 | 0.210 |
Why?
|
| Physical Stimulation | 1 | 2024 | 68 | 0.210 |
Why?
|
| Dysphonia | 1 | 2023 | 15 | 0.210 |
Why?
|
| Voice | 1 | 2023 | 12 | 0.210 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 204 | 0.190 |
Why?
|
| Laryngeal Muscles | 1 | 2022 | 12 | 0.190 |
Why?
|
| Hand | 1 | 2024 | 163 | 0.190 |
Why?
|
| Larynx | 1 | 2023 | 63 | 0.190 |
Why?
|
| Voice Disorders | 1 | 2022 | 26 | 0.190 |
Why?
|
| Voice Quality | 1 | 2022 | 22 | 0.190 |
Why?
|
| Laryngeal Diseases | 1 | 2022 | 30 | 0.190 |
Why?
|
| Viral Load | 1 | 2024 | 506 | 0.190 |
Why?
|
| Pakistan | 1 | 2021 | 77 | 0.180 |
Why?
|
| Deglutition Disorders | 1 | 2023 | 148 | 0.170 |
Why?
|
| Cerebral Cortex | 1 | 2024 | 461 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1252 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2560 | 0.150 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2018 | 7 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2018 | 20 | 0.150 |
Why?
|
| Mutation | 3 | 2024 | 4013 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2024 | 747 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 72 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 327 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 553 | 0.140 |
Why?
|
| Humans | 15 | 2024 | 141197 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 464 | 0.120 |
Why?
|
| Burnout, Professional | 1 | 2022 | 455 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2018 | 792 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 849 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 677 | 0.110 |
Why?
|
| Prevalence | 1 | 2021 | 2772 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1123 | 0.100 |
Why?
|
| Physicians | 1 | 2022 | 934 | 0.100 |
Why?
|
| Atrophy | 2 | 2022 | 193 | 0.090 |
Why?
|
| Caregivers | 1 | 2020 | 932 | 0.090 |
Why?
|
| Animals | 6 | 2023 | 37663 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 5636 | 0.080 |
Why?
|
| Male | 4 | 2024 | 69789 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1983 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 39181 | 0.070 |
Why?
|
| Female | 4 | 2024 | 75522 | 0.070 |
Why?
|
| Young Adult | 1 | 2024 | 13673 | 0.070 |
Why?
|
| Risk Factors | 1 | 2021 | 10438 | 0.070 |
Why?
|
| United States | 1 | 2021 | 15220 | 0.050 |
Why?
|
| Speech Acoustics | 1 | 2023 | 12 | 0.050 |
Why?
|
| Laryngeal Mucosa | 1 | 2023 | 8 | 0.050 |
Why?
|
| Acoustics | 1 | 2023 | 45 | 0.050 |
Why?
|
| Epiglottis | 1 | 2023 | 3 | 0.050 |
Why?
|
| Deglutition | 1 | 2023 | 71 | 0.050 |
Why?
|
| Video Recording | 1 | 2023 | 190 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2023 | 169 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 132 | 0.050 |
Why?
|
| Cicatrix | 1 | 2022 | 67 | 0.050 |
Why?
|
| Posture | 1 | 2022 | 195 | 0.040 |
Why?
|
| Perception | 1 | 2023 | 376 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 7856 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2023 | 316 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 222 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 546 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 24576 | 0.040 |
Why?
|
| Beclin-1 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2018 | 3 | 0.040 |
Why?
|
| U937 Cells | 1 | 2018 | 26 | 0.040 |
Why?
|
| Receptors, Interferon | 1 | 2018 | 52 | 0.040 |
Why?
|
| Multigene Family | 1 | 2018 | 202 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 406 | 0.030 |
Why?
|
| Overweight | 1 | 2022 | 587 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 34438 | 0.030 |
Why?
|
| Emotions | 1 | 2022 | 575 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2018 | 215 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 287 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 914 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1357 | 0.030 |
Why?
|
| Health Personnel | 1 | 2022 | 737 | 0.030 |
Why?
|
| Hypoxia | 1 | 2022 | 1164 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1768 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1467 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2018 | 852 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 2239 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1487 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1764 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3470 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 2098 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 7739 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7070 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 3004 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 11120 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 5144 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 16273 | 0.010 |
Why?
|
| Child | 1 | 2022 | 22310 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 18055 | 0.010 |
Why?
|